Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03102632 · ClinicalTrials.gov registry record · NA
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease
A NA study of Autosomal Dominant Polycystic Kidney, sponsored by The Rogosin Institute.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03102632 is a NA study of Autosomal Dominant Polycystic Kidney that has completed, run by The Rogosin Institute. The registered enrollment target is 10 participants, below the 103-participant average among 6 other Autosomal Dominant Polycystic Kidney trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03102632, a NA study of Autosomal Dominant Polycystic Kidney, has completed, sponsored by The Rogosin Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients affected by Autosomal Dominant Polycystic Kidney Disease (ADPKD) need a safe and effective long-term treatment regimen. Unfortunately, there are still no disease-specific treatment for ADPKD approved in the US. A rational step towards identifying such agents is to test therapies that have a proven safety profile with mechanisms of action that can counter the disease progression. The purpose of this study is to investigate whether drinking increased amounts of water (water loading) might slow down polycystic kidney growth or kidney function decline. Water loading can cause the suppression of a pathway that causes fluid buildup and cyst growth. High water intake has been safely used in the clinical setting, such as in the case of kidney stone therapy. New York State tap water is widely available and safe, making it highly cost-effective as well.
Conditions Studied
Interventions
- OTHER High Water Intake
Study Locations (1)
New York
- The Rogosin Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2021-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03102632
The ClinicalTrials.gov registry entry for NCT03102632 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 6 other Autosomal Dominant Polycystic Kidney trials with a reported enrollment target (90% lower). The listed sponsor is The Rogosin Institute, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autosomal Dominant Polycystic Kidney appearing as the primary indexed condition, and to 1 intervention - of which High Water Intake is the first listed.
NCT03102632 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03102632 about?
NCT03102632 is a clinical study titled "A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease". Patients affected by Autosomal Dominant Polycystic Kidney Disease (ADPKD) need a safe and effective long-term treatment regimen. Unfortunately, there are still no disease-specific treatment for ADPKD approved in the US. A rational step towards identifying such agents is to test therapies that have a...
What is the current status of trial NCT03102632?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2017-06-01. Estimated completion is 2021-12-31.
What conditions does trial NCT03102632 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney.
What interventions are being tested in trial NCT03102632?
The interventions under investigation include: High Water Intake (OTHER).
Who is sponsoring clinical trial NCT03102632?
This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03102632 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD
ACTIVE NOT RECRUITING · NA
-
Daily Caloric Restriction in ADPKD
ACTIVE NOT RECRUITING · NA
-
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
RECRUITING · Phase 2
-
A Prospective Observational Study of Foam Sclerotherapy .
RECRUITING
-
Statin Therapy in Patients With Early Stage ADPKD
ACTIVE NOT RECRUITING · Phase 4
-
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.